Literature DB >> 35607369

Positive therapy outcome of lung squamous cell cancer: A case report.

Ying Liu1, Jian Yang2, Xue-Jia Sun3, Sheng-Nan Lu4, Shi Liu5.   

Abstract

Lung cancer is a rapidly progressing disease with a poor prognosis. Lung squamous cell cancer (LSCC) accounts for 20-30% of lung cancer cases. Conventional chemotherapy and radiotherapy are the common options for LSCC. Nevertheless, the outcomes of these treatments are still unsatisfactory. The present report describes a rare case of LSCC with pericardial, cervical lymph node and extensive mediastinal lymph node metastases, who still survives today, in March 2022, more than 10 years after therapy and, therefore, this case study indicates a possible treatment regimen for patients with a similar condition. In conclusion, gemcitabine and cisplatin followed by radiotherapy were an effective treatment against pericardial and lymph node metastases from LSCC.
Copyright © 2020, Spandidos Publications.

Entities:  

Keywords:  case report; cisplatin; gemcitabine; lung squamous cell cancer; metastasis; radiotherapy

Year:  2022        PMID: 35607369      PMCID: PMC9121202          DOI: 10.3892/etm.2022.11360

Source DB:  PubMed          Journal:  Exp Ther Med        ISSN: 1792-0981            Impact factor:   2.751


  13 in total

1.  Results from a single institution phase II trial of concurrent docetaxel/carboplatin/radiotherapy followed by surgical resection and consolidation docetaxel/carboplatin in stage III non-small-cell lung cancer.

Authors:  Millie Das; Jessica S Donington; James Murphy; Margaret Kozak; Neville Eclov; Richard I Whyte; Chuong D Hoang; Lisa Zhou; Quynh-Thu Le; Billy W Loo; Heather Wakelee
Journal:  Clin Lung Cancer       Date:  2011-07-14       Impact factor: 4.785

Review 2.  Current WHO guidelines and the critical role of immunohistochemical markers in the subclassification of non-small cell lung carcinoma (NSCLC): Moving from targeted therapy to immunotherapy.

Authors:  Lais Osmani; Frederic Askin; Edward Gabrielson; Qing Kay Li
Journal:  Semin Cancer Biol       Date:  2017-11-26       Impact factor: 15.707

Review 3.  Lung cancer: Biology and treatment options.

Authors:  Hassan Lemjabbar-Alaoui; Omer Ui Hassan; Yi-Wei Yang; Petra Buchanan
Journal:  Biochim Biophys Acta       Date:  2015-08-19

4.  Gemcitabine, cisplatin, and hyperfractionated accelerated radiotherapy for locally advanced non-small cell lung cancer.

Authors:  Matjaz Zwitter; Viljem Kovac; Uros Smrdel; Primoz Strojan
Journal:  J Thorac Oncol       Date:  2006-09       Impact factor: 15.609

5.  NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 5.2018.

Authors:  David S Ettinger; Dara L Aisner; Douglas E Wood; Wallace Akerley; Jessica Bauman; Joe Y Chang; Lucian R Chirieac; Thomas A D'Amico; Thomas J Dilling; Michael Dobelbower; Ramaswamy Govindan; Matthew A Gubens; Mark Hennon; Leora Horn; Rudy P Lackner; Michael Lanuti; Ticiana A Leal; Rogerio Lilenbaum; Jules Lin; Billy W Loo; Renato Martins; Gregory A Otterson; Sandip P Patel; Karen Reckamp; Gregory J Riely; Steven E Schild; Theresa A Shapiro; James Stevenson; Scott J Swanson; Kurt Tauer; Stephen C Yang; Kristina Gregory; Miranda Hughes
Journal:  J Natl Compr Canc Netw       Date:  2018-07       Impact factor: 11.908

6.  A phase II single-arm study of induction chemotherapy with cisplatin and gemcitabine followed by concurrent cisplatin and gemcitabine with thoracic radiation for unresectable locally advanced non-small cell lung cancer.

Authors:  Peter Driesen; Marc Lambrechts; Kees Kraaij; Victoria Soldatenkova; Nadia Chouaki; Benoit Colinet
Journal:  Ther Adv Med Oncol       Date:  2013-05       Impact factor: 8.168

7.  Gemcitabine combined with cisplatin as adjuvant chemotherapy for non-small cell lung cancer: A retrospective analysis.

Authors:  Di Ma; Jing Wang; Xuezhi Hao; Yan Wang; Xingsheng Hu; Puyuan Xing; Junling Li
Journal:  Thorac Cancer       Date:  2017-07-26       Impact factor: 3.500

8.  Comparative efficacy and safety for different chemotherapy regimens used concurrently with thoracic radiation for locally advanced non-small cell lung cancer: a systematic review and network meta-analysis.

Authors:  Tingting Liu; Zheng He; Jun Dang; Guang Li
Journal:  Radiat Oncol       Date:  2019-03-29       Impact factor: 3.481

Review 9.  Meta-analysis of first-line therapies with maintenance regimens for advanced non-small-cell lung cancer (NSCLC) in molecularly and clinically selected populations.

Authors:  Pui San Tan; Marcel Bilger; Gilberto de Lima Lopes; Sanchalika Acharyya; Benjamin Haaland
Journal:  Cancer Med       Date:  2017-07-03       Impact factor: 4.452

Review 10.  Update 2020: Management of Non-Small Cell Lung Cancer.

Authors:  Mariam Alexander; So Yeon Kim; Haiying Cheng
Journal:  Lung       Date:  2020-11-11       Impact factor: 2.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.